对成骨不全症和严重肥胖患者进行减肥手术治疗。
Treatment with bariatric surgery in patients with osteogenesis imperfecta and severe obesity.
作者信息
Hald Jannie Dahl, Hald Asta-Marie Welander, Harsløf Torben, Langdahl Bente, Bruun Jens Meldgaard
机构信息
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Centre for Rare Diseases, Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
出版信息
Bone Rep. 2024 Oct 21;23:101811. doi: 10.1016/j.bonr.2024.101811. eCollection 2024 Dec.
Abstract
•Skeletal fragility and immobility in osteogenesis imperfecta may lead to obesity.•Bariatric surgery is an efficient treatment for severe obesity.•Bone turnover and BMD should be monitored closely during periods of rapid weight loss.•Bone protective treatment minimizes bone deterioration before weight loss.•Bariatric surgery may be considered in mild osteogenesis imperfecta.
摘要
•成骨不全症中的骨骼脆弱和行动不便可能导致肥胖。
•减肥手术是治疗重度肥胖的有效方法。
•在快速减重期间应密切监测骨转换和骨密度。
•骨保护治疗可在减重前将骨质恶化降至最低。
•轻度成骨不全症患者可考虑进行减肥手术。
相似文献
1
Treatment with bariatric surgery in patients with osteogenesis imperfecta and severe obesity.对成骨不全症和严重肥胖患者进行减肥手术治疗。
Bone Rep. 2024 Oct 21;23:101811. doi: 10.1016/j.bonr.2024.101811. eCollection 2024 Dec.
2
Femoral geometric parameters and BMD measurements by DXA in adult patients with different types of osteogenesis imperfecta.成骨不全症成年患者的股骨几何参数和 DXA 骨密度测量。
Skeletal Radiol. 2013 Feb;42(2):187-94. doi: 10.1007/s00256-012-1512-4. Epub 2012 Sep 7.
3
Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.口服阿仑膦酸钠对成骨不全成年患者骨密度的影响：一项为期3年的随机安慰剂对照试验。
J Bone Miner Res. 2006 Feb;21(2):300-6. doi: 10.1359/JBMR.051015. Epub 2005 Oct 24.
4
Osteogenesis imperfecta and the teeth, eyes, and ears-a study of non-skeletal phenotypes in adults.成骨不全症与牙齿、眼睛和耳朵：成年人的非骨骼表型研究。
Osteoporos Int. 2018 Dec;29(12):2781-2789. doi: 10.1007/s00198-018-4663-x. Epub 2018 Aug 24.
5
Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.唑来膦酸对成骨不全成年患者的急性和长期影响。一项为期五年随访的西班牙观察性研究。
Endocrinol Diabetes Nutr (Engl Ed). 2019 Feb;66(2):108-116. doi: 10.1016/j.endinu.2018.05.015. Epub 2018 Aug 1.
6
Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study.成骨不全症患者在双膦酸盐药物假期期间的骨骼结局：一项真实世界研究。
Front Endocrinol (Lausanne). 2022 Sep 26;13:901925. doi: 10.3389/fendo.2022.901925. eCollection 2022.
7
Weight loss surgery improves quality of life in pediatric patients with osteogenesis imperfecta.减肥手术可改善成骨不全症患儿的生活质量。
Surg Obes Relat Dis. 2017 Jan;13(1):41-44. doi: 10.1016/j.soard.2015.11.029. Epub 2015 Dec 2.
8
Bariatric surgery and skeletal health: A narrative review and position statement for management by the European Calcified Tissue Society (ECTS).减重手术与骨骼健康：欧洲钙化组织协会（ECTS）的管理叙述性综述和立场声明。
Bone. 2022 Jan;154:116236. doi: 10.1016/j.bone.2021.116236. Epub 2021 Oct 22.
9
Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.地诺单抗对三名成骨不全女性患者骨质疏松症的疗效
Tohoku J Exp Med. 2017 Jun;242(2):115-120. doi: 10.1620/tjem.242.115.
10
Multi-omics analyses reveal aberrant differentiation trajectory with WNT1 loss-of-function in type XV osteogenesis imperfecta.多组学分析揭示了 WNT1 功能丧失型 XV 型成骨不全症中异常的分化轨迹。
J Bone Miner Res. 2024 Sep 2;39(9):1253-1267. doi: 10.1093/jbmr/zjae123.
本文引用的文献
1
Setrusumab for the treatment of osteogenesis imperfecta: 12-month results from the phase 2b asteroid study.Setrusumab 治疗成骨不全症：2b 期小行星研究的 12 个月结果。
J Bone Miner Res. 2024 Sep 2;39(9):1215-1228. doi: 10.1093/jbmr/zjae112.
2
Body mass index and all-cause mortality in a 21st century U.S. population: A National Health Interview Survey analysis.21 世纪美国人群的体重指数与全因死亡率：一项全国健康访谈调查分析。
PLoS One. 2023 Jul 5;18(7):e0287218. doi: 10.1371/journal.pone.0287218. eCollection 2023.
3
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.三重激素受体激动剂 Retatrutide 治疗肥胖症的 2 期临床试验
N Engl J Med. 2023 Aug 10;389(6):514-526. doi: 10.1056/NEJMoa2301972. Epub 2023 Jun 26.
4
Tirzepatide Once Weekly for the Treatment of Obesity.司美格鲁肽每周一次治疗肥胖症。
N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.
5
The role of osteoanabolic agents in the management of patients with osteoporosis.骨合成代谢药物在骨质疏松症患者管理中的作用。
Postgrad Med. 2022 Aug;134(6):541-551. doi: 10.1080/00325481.2022.2069582. Epub 2022 May 30.
6
The Impact of Bariatric Surgery on Bone Health: State of the Art and New Recognized Links.减重手术对骨骼健康的影响：现状与新的认识关联
Horm Metab Res. 2022 Mar;54(3):131-144. doi: 10.1055/a-1767-5581. Epub 2022 Mar 11.
7
Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants.代谢性减重手术与有或无糖尿病成人长期生存的关联：一项对 174772 名参与者的匹配队列和前瞻性对照研究的一阶段荟萃分析。
Lancet. 2021 May 15;397(10287):1830-1841. doi: 10.1016/S0140-6736(21)00591-2. Epub 2021 May 6.
8
Comparative efficacy of different weight loss treatments on knee osteoarthritis: A network meta-analysis.不同减肥治疗方法对膝骨关节炎疗效的比较：网状荟萃分析。
Obes Rev. 2021 Aug;22(8):e13230. doi: 10.1111/obr.13230. Epub 2021 Apr 15.
9
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
10
Association of Bariatric Surgery With Risk of Fracture in Patients With Severe Obesity.肥胖症患者行减重手术后骨折风险的相关性研究。
JAMA Netw Open. 2020 Jun 1;3(6):e207419. doi: 10.1001/jamanetworkopen.2020.7419.
Zotero 插件